With the grant of additional patents in the USA (US1249744) and Japan (JP7791867), mAbsolve’s patent coverage has been further extended to include nucleic acids and Fc fusion proteins which incorporate the STR technology. These divisional patents build on our existing granted patents in the United States, Japan, United Kingdom, Canada and Australia, which cover antibodies … Read more
A new generation of antibody variant developed by mAbsolve has been licensed to Novalgen for evaluation in their pipeline of therapeutic antibodies intended for treatment of cancer, leukaemias and cardiovascular disease. Mr Nilesh Modi, COO of Novalgen, said: I’m delighted to be working with the newly formed mAbsolve team, who individually have fantastic track records. … Read more